ACADIA Pharmaceuticals/$ACAD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Ticker
$ACAD
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
654
ISIN
US0042251084
Website
ACAD Metrics
BasicAdvanced
$3.7B
15.99
$1.37
0.48
-
Price and volume
Market cap
$3.7B
Beta
0.48
52-week high
$25.23
52-week low
$13.40
Average daily volume
1.9M
Financial strength
Current ratio
2.879
Quick ratio
2.629
Long term debt to equity
5.833
Total debt to equity
5.833
Profitability
EBITDA (TTM)
101.665
Gross margin (TTM)
59.74%
Net profit margin (TTM)
22.97%
Operating margin (TTM)
8.87%
Effective tax rate (TTM)
13.58%
Revenue per employee (TTM)
$1,520,000
Management effectiveness
Return on assets (TTM)
5.56%
Return on equity (TTM)
37.24%
Valuation
Price to earnings (TTM)
15.995
Price to revenue (TTM)
3.652
Price to book
4.77
Price to tangible book (TTM)
5.63
Price to free cash flow (TTM)
73.355
Free cash flow yield (TTM)
1.36%
Free cash flow per share (TTM)
29.84%
Growth
Revenue change (TTM)
22.42%
Earnings per share change (TTM)
-13,261.73%
3-year revenue growth (CAGR)
26.42%
10-year revenue growth (CAGR)
152.65%
3-year earnings per share growth (CAGR)
0.86%
10-year earnings per share growth (CAGR)
1.66%
What the Analysts think about ACAD
Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.
Bulls say / Bears say
The U.S. Court of Appeals upheld the validity of Acadia's patent for Nuplazid, securing protection until 2030 and 2038 for different formulations, which strengthens the company's market position and revenue prospects. (reuters.com)
Acadia expanded its rights to trofinetide (Daybue) outside North America and acquired global rights to NNZ-2591, enhancing its pipeline and potential market reach. (fool.com)
JPMorgan upgraded Acadia's stock to 'overweight' with a price target of $32, indicating confidence in the company's growth prospects. (fool.com)
Acadia's Phase 3 trial for pimavanserin in treating schizophrenia failed to meet its primary endpoint, leading to the discontinuation of further trials for this indication. (investopedia.com)
Guggenheim downgraded Acadia's stock to 'neutral' and lowered the price target to $20, reflecting concerns about the company's near-term growth. (marketbeat.com)
Insider selling activity, including significant share sales by executives, may indicate a lack of confidence in the company's future performance. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
ACAD Financial Performance
Revenues and expenses
ACAD Earnings Performance
Company profitability
ACAD News
AllArticlesVideos
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 weeks ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 weeks ago
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals (ACAD) has a market cap of $3.7B as of July 15, 2025.
What is the P/E ratio for ACADIA Pharmaceuticals stock?
The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 15.99 as of July 15, 2025.
Does ACADIA Pharmaceuticals stock pay dividends?
No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next ACADIA Pharmaceuticals dividend payment date?
ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.
What is the beta indicator for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.